Genotyping of the chloroquine-resistance biomarker pfcr (Plasmodium falciparum chloroquine resistance transporter gene) suggests that, in the absence of chloroquine pressure, Plasmodium falciparum parasites in Malawi have reverted to chloroquine sensitivity. However, malaria infections in Africa are commonly polyclonal, and standard PCRs cannot detect minority genotypes if present in <20% of the parasites in an individual host. We have developed a multiple site–specific heteroduplex tracking assay (MSS-HTA) that can detect pfcr 76T mutant parasites consisting of as little as 1% of the parasite population. In clinical samples, no pfcr 76T was detected in 87 pregnant Malawian women by standard PCR. However, 22 (25%) contained minority-variant resistant genotypes detected by the MSS-HTA. These results were confirmed by subcloning and sequencing. This finding suggests that the chloroquine-resistant genotype remains common in Malawians and that PCR-undetectable drug-resistant genotypes may be present in disease-endemic populations. Surveillance for minority-variant drug-resistant mutations may be useful in making antimalarial drug policy.

Drug-resistant Plasmodium falciparum malaria continues to be a growing health problem throughout most of the world (1). To combat this threat, governments and aid agencies need accurate drug resistance surveillance data. The World Health Organization has stressed the need for methods of detecting molecular markers of drug resistance that will be useful in predicting responses to both clinical and public health interventions (2). This has been difficult in highly malaria-endemic areas, where infections are almost always polyclonal (3,4). In patients with polyclonal infections, small drug-resistant parasite populations (minority variants) may be masked by larger drug-sensitive populations because standard PCRs are relatively insensitive to minority variants (2). Therefore, new methods capable of detecting these subpopulations may lead to better drug resistance surveillance and provide a better tool to predict outcome.

We describe a new multiple site-specific heteroduplex tracking assay (MSS-HTA) for detecting the pfcr (Plasmodium falciparum chloroquine resistance transporter gene) K76T mutation. This mutation in a putative transporter gene is well-associated with chloroquine resistance in P. falciparum (5). The MSS-HTA was compared with a standard allele-restricted PCR (ARPCR) in clinical samples from Malawi, a country where standard PCR analyses and a recent clinical trial have suggested that chloroquine-resistant malaria has disappeared (6–9).

Materials and Methods

Study Samples

Informed consent, as approved by the ethics committees of the University of North Carolina and the Malawi College of Medicine/Ministry of Health, was obtained from all participants in this research study. The Malaria and HIV in Pregnancy Study (MHP) patient samples originated from a study of pregnant women attending Queen Elizabeth Central Hospital, an urban hospital in Blantyre. The complete characteristics of the cohort and study design have been described elsewhere (10). The Mpemba and Madziabango (MM) patient samples were also collected from pregnant women as part of a pilot randomized, open-label, efficacy study of intermittent preventive treatment in pregnancy at rural health clinics. The diversity of these infections, as well as the cohort and study design, has been described elsewhere (3). The characteristics of the patient samples used in this study are outlined in Table 1. All samples...
Table 1. Characteristics of patient samples*

| Characteristic          | Value (range) |
|-------------------------|---------------|
| Age (y)                 |               |
| Total                   | 21.9 (15–35)  |
| MHP patients            | 23.7 (17–31)  |
| MM patients             | 21.2 (15–35)  |
| Parasite density (no. parasites/200 leukocytes) |           |
| Total                   | 243.8 (4–2.202) |
| MHP patients            | 599.7 (4–2.202) |
| MM patients             | 83.3 (5–750)  |
| Gravidity               |               |
| Total                   | 2.26 (1–9)    |
| MHP patients            | 2.37 (1–3)    |
| MM patients             | 2.21 (1–9)    |
| Anemia (hemoglobin <11 g/dL) |          |
| Total                   | 64/87 (73.6%) |
| MHP patients            | 21/27 (77.8%) |
| MM patients             | 43/60 (71.7%) |
| HIV status              |               |
| Total†                  | 38/58 (65.5%) |
| MHP patients            | 27/27 (100%)  |
| MM patients             | 11/31 (35.5%) |
| Clinical symptoms‡      |               |
| Fever                   | 14/27 (51.8%) |
| Headache                | 18/27 (66.7%) |
| General body pain       | 13/27 (48.1%) |
| Preventive measures‡    |               |
| Bed net use§            | 6/19 (31.6%)  |

*No data available for 8 patients.
‡Data only available for MHP patients.
§No data available for 8 patients.

Malaria DNA Stocks

All malaria DNA used in the experiments, other than clinical samples, was from MR-4 (www.mr4.org). Wild type (pfcrt K76) was from P. falciparum strain 3d7 (MR-4, MRA-102G). Two strains of mutant DNA (pfcrt K76T) were used in these experiments: P. falciparum strain K1 (MR4, MRA-159G) was used for the CVIET-resistant haplotype, based on the amino acid sequence from codon 72 to codon 76, and P. falciparum strain 7g8 (MR4, MRA-152G) was used for the SVMNT-resistant haplotype.

Generation of Heteroduplex Tracking Assay (HTA) Probe

Wild-type P. falciparum DNA was amplified with a Peltier thermal cycler (MJ Research, Waltham, MA, USA) in a volume of 50 μL. The reaction conditions consisted of 5 μL DNA, 2.5 U HotStar Taq DNA polymerase (QIAGEN, Valencia, CA, USA), 5 μL 10× PCR buffer, 1 μL deoxyribonucleoside triphosphate mix (catalog no. U1511, Promega, Madison, WI, USA), and 2,000 nmol/L forward and reverse primers CRT HTA F: 5′-GGAAAATGGCTCACGTTTTAGG-3′, and CRT HTA R: 5′-TGTGAGTTTCGGATGT-TACAAAA-3′. This reaction was amplified by preheating to 95°C for 15 min, followed by 35 cycles of 95°C for 30 s, 50°C for 30 s, and 72°C for 1 min. The reaction was completed with a 10-min hold at 72°C. The 250-bp PCR product was cloned into a PCR2.1 TOPO plasmid as described in the protocol of the Topo TA cloning kit (Invitrogen, Carlsbad, CA, USA), and the sequence was confirmed at the University of North Carolina-Chapel Hill Automated DNA Sequencing Facility. Mutations were randomly introduced into the construct at the −3, −1, +1, and +3 nt relative to the single nucleotide polymorphism involved with the pfcrt K76T mutation using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) (11). Potential probes were then amplified by colony PCR under the conditions noted above.

Potential probes were screened against wild-type and resistant PCR amplicons by using a heteroduplex mobility assay on an 8% polyacrylamide gel in 1% Tris-borate-EDTA buffer. After an annealing reaction, probes were evaluated for differential migration between the lanes containing the different amplicons. The annealing reaction containing 4 μL PCR product from a colony of a potential probe mixed with 4 μL PCR product of control DNA, 1 μL 100-pmol CRT HTA F primer, 1 μL 100-pmol CRT HTA R primer, and 2 μL 6× loading dye (Promega) was heated to 95°C for 2 min and then allowed to cool at 25°C for 5 min. The annealing reaction was then loaded into the wells of a nondenaturing acrylamide gel and run at a constant current of 17 mA for 5 h per gel with an SE 600 Gel Electrophoresis Unit (Amersham Biosciences, Piscataway, NJ, USA). DNA was visualized by UV after staining in an ethidium bromide solution for 20 min and destaining in double-distilled H2O for 15 min. In all, 77 potential probes were screened. The successful probe was sequenced and shown a −1 A to C mutation (GenBank accession no. submission in process).

The plasmid containing the probe was harvested by using Promega Wizard MiniPreps (Promega) and then amplified according to the conditions noted above. The PCR product was the blunt-end cloned into the pT7Blue vector with the Perfectly Blunt Cloning kit (Novagen, Inc., Madison, WI, USA). The probe was radiolabeled according to the methods of Ngrenngarmelrt et al. (12).

HTA

The MSS-HTA was performed under the conditions noted by Ngrenngarmelrt et al. with some modifications (12). An annealing reaction consisting of 4 μL PCR product (either a control or sample DNA) was mixed with 1 μL 10× annealing buffer (1 mol/L NaCl, 100 mmol/L Tris-HCl, pH 7.5, 20 mmol/L EDTA), 2 μL 6× loading dye, 500 nmol/L CRT HTA F primer, 500 nmol/L CRT HTA R primer, and
ARPCR
ARPCR detection of pfcr 76T was performed according to the methods described by Djimde et al. (13). The primers for the assay were modified according to Wilson et al. (8).

Minority Variant Detection
MSS-HTA and ARPCR were both run against mixtures of control DNA in quadruplicate. Differing proportions of wild-type genomic DNA and CVIET-resistant haplotype genomic DNA were mixed to a final sample concentration of 0.1 ng/μL. If a band was not visible to the eye, or only visible in 1 replicate, it was not counted.

Detection of Minor Variants in Clinical Samples
MSS-HTA was used to screen clinical samples in duplicate. All MHP samples were assayed by MSS-HTA and ARPCR. MM samples were all initially assayed by MSS-HTA. ARPCR was performed on all samples positive by HTA and on a random selection of 20 MSS-HTA–negative samples.

Ten samples that were positive by MSS-HTA were selected and Topo TA–cloned (Invitrogen). Twenty-five colonies from each of these 10 samples were screened by colony real-time PCR to determine if the plasmid construct contained a wild-type or resistant pfcr insert (8,12). A selection of 2 mutant and 4 wild-type plasmids isolated from these colonies was then sequenced.

Results
DNA from standard culture strains was used. The MSS-HTA probe formed heteroduplexes with different mobilities when annealed to P. falciparum DNA amplicons from wild-type parasites (Figure, panel A, lane C) and from parasites containing each of the 2 major resistant haplotypes: SVMNT (Figure, panel A, lane D) and CVIET (Figure, panel B, lane E).

The sensitivities of MSS-HTA and ARPCR to detect subpopulations of resistant pfcr were tested by using artificial mixtures of wild-type and mutant genomic P. falciparum DNA. MSS-HTA detected mutant CVIET variants comprising as little as 1% of the total population (Figure, panel A, lanes N and O). In contrast, the allele-restricted PCR could not detect mutants comprising <20% of the total population (Figure, panel B, lanes I and J). In addition, the MSS-HTA accurately and reproducibly quantified mutant populations comprising as little as 1% of the sample (Table 2).

The 2 assays were then applied to clinical samples from malaria-positive Malawian pregnant women (Table 3). In total, 87 clinical samples were screened. Twenty-seven samples (MHP) were collected as part of a study of pregnant women conducted in Blantyre. CVIET-resistant haplotype P. falciparum DNA was detected in 1 sample (3.7%) by MSS-HTA and in none by ARPCR. In addition, 60 samples (MM) from 2 rural health centers were initially screened with the MSS-HTA. This method detected CVIET-resistant haplotype DNA in 21 (35%) of the clinical samples. In these samples, the amount of mutant genotype was quantified with the phosphorimager and averaged 3.3% (SD 1.4, range 1.1%–8.3%) of the parasite population. ARPCR was conducted on all samples positive by MSS-HTA as well as 20 random samples that were negative by MSS-HTA and failed to detect any samples with mutant DNA.

To confirm the presence of mutant DNA in the samples, 10 samples positive by MSS-HTA were cloned and 25 colonies from each sample were screened by real-time PCR. Of the 250 screened colonies, 6 (2.4%) had the mutant genotype in the plasmid construct. Two mutant and 4
wild-type plasmid constructs were then sequenced to confirm the MSS-HTA results. All of the mutant plasmid constructs that were sequenced contained the CVIET-resistant haplotype, and none of the wild-type plasmid constructs contained the single nucleotide polymorphism associated with pfcr76T.

Discussion

Minority-variant drug-resistant parasite populations that were undetectable by PCR were found to be common in polyclonal Malawian P. falciparum infections. The presence of minority drug-resistant variants is consistent with results of other studies, which have shown patients with genotypically wild-type infections before therapy exhibiting genotypically mutant infections after unsuccessful chemotherapy (14,15). In Malawi, where chloroquine was replaced with sulfadoxine-pyrimethamine in 1993, the prevalence of the resistance marker pfcr76T, as determined by PCR, has been reported to have almost disappeared (6–9). However, our data suggest that the reversion to genotypically sensitive malaria is incomplete and that minority pfcr76T–bearing parasite strains are “lurking” within persons at levels undetectable by standard PCR. One caveat is that our study population comprised pregnant women with high HIV prevalence, so whether the results are applicable to the general population is unclear.

Minority-variant drug-resistant mutations are important in other diseases, such as HIV (16). The presence of minority-variant drug-resistant mutations in P. falciparum has been previously demonstrated by subcloning dihydrofolate reductase genes into yeast vectors and growing them under drug pressure (17). However, this technique cannot determine the frequency of minority variants either in a single host or in a population. To our knowledge, our results show, for the first time, that minority-variant drug-resistant mutations, representing several percentages of the parasites in a single host, are common in populations.

In response to the apparent reemergence of genotypically sensitive malaria, Laufer et al. recently completed a chloroquine efficacy trial in pediatric patients from urban Blantyre (9). The cumulative efficacy of chloroquine was 99% (95% confidence intervals 93%–100%) with only 1 treatment failure occurring in the chloroquine arm. The high efficacy rate of chloroquine therapy is not inconsistent with the results of our study. In urban Blantyre, we only found 1 patient with minority-variant pfcr76T. In addition, successful response to therapy requires not only susceptibility of the parasite to the drug but also factors such as acquired immunity, drug absorption, and nutrition. At this point, it is still unclear how minority-variant drug-resistant parasites will interact with these other factors. Further research in this area is needed.

Significantly more patients carried minority-variant pfcr76T (35%) at the rural sites (p = 0.001, Fisher exact test) than at the urban site (3.7%). Why such a marked difference was found in the prevalence of pfcr76T between the 2 sites is not clear. One possibility is that the transition from chloroquine to sulfadoxine-pyrimethamine may have occurred later in rural areas than in urban areas. Also, limited drug pressure may continue to be exerted on the parasites within Malawi because, as of early 2006, chloroquine was still available in local pharmacies (17). Another possible factor that may influence the prevalence of minority-variant drug-resistant parasites is external pressure from areas of high-level resistance such as Zambia and Mozambique. Mpemba and Madziabango lie on a major highway between Blantyre and the border with Zambia. Importation of cases of malaria by travel along this highway may lead to a gradient of resistance extending from the border to Blantyre. More studies on the epidemiology of minority-variant pfcrk76T are needed to better understand the causes of this difference in the prevalence of pfcr76T.

In conclusion, MSS-HTAs can gather information on lurking drug resistance overlooked by standard PCRs.

Table 2. Sensitivity testing of HTA on mixes of genomic DNA at known concentrations*

| % Mutant | Average wild-type (%) | SD weight | Average mutant (%) | SD mutant |
|----------|-----------------------|-----------|-------------------|-----------|
| 50       | 48.1                  | 2.39      | 51.9              | 2.39      |
| 20       | 77.0                  | 2.56      | 23.0              | 2.55      |
| 10       | 88.9                  | 2.34      | 11.1              | 2.34      |
| 5        | 94.8                  | 0.95      | 5.2               | 0.95      |
| 1        | 98.7                  | 0.22      | 1.3               | 0.22      |
| 0.1      | 100                   | 0         | ND                | ND        |

*HTA, heteroduplex tracking assay; ND, none detected.

Table 3. Detection of pfcr76T in clinical samples*

| Clinical site | No. samples | No. positive samples by HTA (%) | No. positive samples by ARPCR (%) | Avg mutant population by HTA (%) | SD |
|---------------|-------------|--------------------------------|---------------------------------|---------------------------------|----|
| MHP           | 27          | 1 (3.7)†                       | 0 (0)                           | 3.2                             | 0.07|
| MM            | 60          | 21 (35)†                       | 0 (0)                           | 3.3                             | 1.4 |

*HTA, heteroduplex tracking assay; ARPCR, standard allele-restricted PCR; MHP, Malaria and HIV in Pregnancy; MM, Mpemba and Madziabango. †p = 0.001, Fisher exact test.
The method is currently performed by using radiolabeled probes, which may not be feasible in many underdeveloped countries. Implementing this method for public health purposes would require substitution of fluorescently labeled or biotinylated labeled probes for the radioisotope. MSS HTAs for other drug-resistance loci need to be developed so that the clinical and public health implications of minority variants can be fully assessed.

Funding for this project comes from American Society of Public Health/Centers for Disease Control and Prevention S1935-21/21, National Institute of Allergy and Infectious Diseases (NI-AID)/National Institutes of Health (NIH) AI49804, and NIH training grant DHHS/NH/NIAID 5 T32 AI 07001-28: Training in Sexually Transmitted Diseases and AIDS. These agencies had no involvement in the design, collection, analysis, or interpretation of data in this study or in writing this article or submitting it for publication.

Dr Juliano is an Infectious Disease Fellow in training at the University of North Carolina. His research interests focus primarily on drug resistance detection in malaria from Southeast Asia and Africa. He is also interested in clinical tropical medicine.

References
1. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature. 2005;434:214–7.
2. World Health Organization. Susceptibility of Plasmodium falciparum to antimalarial drugs. Report on global monitoring: 1996–2004. Geneva: The Organization; 2005.
3. Kwiek JJ, Alker AP, Wenink EC, Chaponda M, Kalilani LV, Meshnick SR. Estimating true antimalarial efficacy by heteroduplex tracking assay in patients with complex Plasmodium falciparum infections. Antimicrob Agents Chemother. 2007;51:521–7.
4. Farnert A, Arez AP, Babiker HA. Genotyping of Plasmodium falciparum infections by PCR: a comparative multicentre study. Trans R Soc Trop Med Hyg. 2001;95:225–32.
5. Bray PG, Martin RE, Tilley L, Ward SA, Kirk K, Fidock DA. Defining the role of PICRT in Plasmodium falciparum chloroquine resistance. Mol Microbiol. 2005;56:323–33.
6. Mita T, Kaneko A, Lumi JK, Bwijo B, Takechi M, Zungu IL, et al. Recovery of chloroquine sensitivity and low prevalence of the Plasmodium falciparum chloroquine resistance transporter gene mutation K76T following the discontinuance of chloroquine use in Malawi. Am J Trop Med Hyg. 2003;68:413–5.
7. Kublin JG, Cortese JF, Njunju EM, Mukadam RA, Wirima JJ, Kazembe PN, et al. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis. 2003;187:1870–5.
8. Wilson PE, Kazadi W, Kamwendo DD, Purfield A, Meshnick SR. Prevalence of pfcrt mutations in Congolese and Malawian Plasmodium falciparum isolates as determined by a new Taqman assay. Acta Trop. 2004;93:97–106.
9. Lauer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK, Takala SL, et al. Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med. 2006;355:1959–66.
10. Mwapasa V, Rogerson SJ, Kwiek JJ, Wilson PE, Milner D, Molyneux ME, et al. Maternal syphilis infection is associated with increased risk of mother-to-child transmission of HIV in Malawi. AIDS. 2006;20:1869–77.
11. Resch W, Parkin N, Stuelke EL, Watkins T, Swanstrom R. A multiple-site-specific heteroduplex tracking assay as a tool for the study of viral population dynamics. Proc Natl Acad Sci U S A. 2001;98:176–81.
12. Ngrenngarmert W, Kwiek JJ, Kamwendo DD, Ritola K, Swanstrom R, Wongsrinchanalai C, et al. Measuring allelic heterogeneity in Plasmodium falciparum by heteroduplex tracking assay. Am J Trop Med Hyg. 2005;72:694–701.
13. Djmde A, Dounou M, Cortese JF, Nayem A, Mouloungui P, Bouattia F, et al. A marker for chloroquine-resistant falciparum malaria. N Engl J Med. 2001;344:257–63.
14. Basco LK, Ndounga M, Ngane VF, Soula G. Molecular epidemiology of malaria in Cameroon. XIV. Plasmodium falciparum chloroquine resistance transporter (PfCRT) gene sequences of isolates before and after chloroquine treatment. Am J Trop Med Hyg. 2002;67:392–5.
15. Jafari S, Le Bras J, Bouchaud O, Durand R. Plasmodium falciparum clonal population dynamics during malaria treatment. J Infect Dis. 2004;189:195–203.
16. Kapoor A, Jones M, Shafer RW, Rhee SY, Kazanjian P, Delwart EL. Sequencing-based detection of low-frequency human immunodeficiency virus type 1 drug-resistant mutants by an RNA/DNA heteroduplex generator-tracking assay. J Virol. 2004;78:7112–23.
17. Mookherjee S, Howard V, Nzila-Mouanda A, Watkins W, Sibley CH. Identification and analysis of dihydrofolate reductase alleles from Plasmodium falciparum present at low frequency in polyclonal patient samples. Am J Trop Med Hyg. 1999;61:131–40.

Address for correspondence: Steven R. Meshnick, Department of Epidemiology, University of North Carolina, School of Public Health, CB#7435, Chapel Hill, NC 27599-7435, USA; email: meshnick@email.unc.edu

All material published in Emerging Infectious Diseases is in the public domain and may be used and reprinted without special permission; proper citation, however, is required.